BioCentury
ARTICLE | Clinical News

BBI608: Phase III discontinued

June 2, 2014 7:00 AM UTC

Dainippon discontinued the double-blind, placebo-controlled, international Phase III CO.23 trial evaluating twice-daily 480 mg BBI608 plus best supportive care (BSC) to treat colorectal cancer after a futility analysis based on DCR of the first 97 patients met the protocol-defined criteria for stopping the trial. The company said no safety concerns were identified, but did not disclose specific DCR data or the futility criteria. The trial enrolled about 280 patients with advanced colorectal cancer who have failed all available therapies. ...